NASDAQ$SDGR
Schrodinger Inc/United States · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported a 29% increase in total revenue compared to Q2 2021, with software revenue up by 25% and drug discovery revenue up by 48%.
Schrödinger reported strong second-quarter results with total revenue reaching $38.5 million, a 29% increase year-over-year. Software and drug discovery segments contributed to this growth, and the company's cash position remained strong. The investigational new drug application for the MALT1 inhibitor, SGR-1505, was cleared for Phase 1 clinical development.
- Total revenue increased by 29% year-over-year, reaching $38.5 million.
- Software revenue grew by 25% compared to the second quarter of 2021, amounting to $30.0 million.
- Drug discovery revenue increased by 48% compared to the second quarter of 2021, reaching $8.5 million.
- The company's investigational new drug application for its MALT1 inhibitor, SGR-1505, has been cleared to proceed to Phase 1 clinical development.
Headline financials
Revenue & EPS history
Schrodinger · Revenue · Quarterly
$38.5M
Revenue by segment
Schrodinger · $38.5M total across 2 segments · Q2 2022
- Software Products & Services$30M+24.8%78.0%
- Drug Discovery$8.46M+47.6%22.0%
Forward guidance
Schrödinger maintained its financial outlook for the fiscal year ending December 31, 2022. For the third quarter of 2022, software revenue is expected to range from $23 million to $25 million.
Tailwinds
- Total revenue is expected to range from $161 million to $181 million, representing 17% to 31% growth over 2021.
- Total software revenue is expected to range from $126 million to $136 million, representing 11% to 20% growth over 2021.
- Total drug discovery revenue is expected to range from $35 million to $45 million, representing 42% to 82% growth over 2021.
- Software gross margin percentage is expected to be in the mid-70s.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-2.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+1.8%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+31.4%
Q4 2021
Best reaction
-29.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +1.9% | +23.0% | |
| Q4 2025 | +8.3% | +5.9% | -6.1% | |
| Q3 2025 | -5.8% | -7.4% | -10.8% | |
| Q1 2025 | +0.6% | +0.2% | +3.8% | |
| Q4 2024 | +2.5% | -2.9% | -8.0% | |
| Q3 2024 | +13.1% | -5.1% | +7.8% | |
| Q2 2024 | +0.1% | -15.7% | -6.8% | |
| Q1 2024 | -4.9% | -1.4% | -11.7% | |
| Q4 2023 | -23.1% | -23.7% | -18.4% | |
| Q3 2023 | +15.3% | +27.5% | +49.7% | |
| Q2 2023 | -26.9% | -27.3% | -29.8% | |
| Q1 2023 | -5.1% | -6.4% | +22.3% | |
| Q4 2022 | +14.5% | +21.7% | +16.8% | |
| Q3 2022 | -14.6% | -15.6% | -29.2% | |
| Q2 2022 | +1.5% | -4.9% | -19.1% | |
| Q1 2022 | -5.5% | -10.5% | +1.5% | |
| Q4 2021 | +31.4% | +45.4% | +36.4% | |
| Q3 2021 | -16.1% | -15.6% | -31.6% | |
| Q2 2021 | -5.1% | -12.1% | -0.1% | |
| Q1 2021 | -6.8% | -4.3% | +19.4% | |
| Q4 2020 | -29.9% | -29.7% | -20.8% | |
| Q3 2020 | +12.4% | +15.8% | +39.6% | |
| Q3 2019 | +12.4% | +15.8% | +39.6% | |
| Q2 2020 | -2.5% | -2.4% | -24.2% | |
| Q1 2020 | -8.1% | +0.5% | +3.0% | |
| Q4 2019 | -14.6% | +8.3% | +1.5% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro